Senzime Joins the Anesthesia Patient Safety Foundation (APSF) as a member of the Corporate Advisory Counsel

NEWS: Uppsala, June 23, 2020. Senzime AB (publ) today announces that they have joined the Anesthesia Patient Safety Foundation (APSF) as a member of the APSF Corporate Advisory Counsel.

At Senzime, our focus on improving patient safety is our top priority. The Anesthesia Patient Safety Foundation (APSF) has a mission to improve continually the safety of patients during anesthesia care by encouraging and conducting safety research and education; patient safety programs and campaigns; national and international exchange of information and ideas.

The purpose of the Corporate Advisory Counsel is for APSF leaders and the foundation’s corporate supporters to work together to achieve the APSF’s mission “that no one shall be harmed by anesthesia care “. “We are proud to support the APSF and participate on the Corporate Advisory Counsel.  Their vision aligns perfectly with our corporate mission to improve peri-operative patient safety.” said Chris Estes, President Senzime Inc, who will serve as the CAC representative.

Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com     

TO THE EDITORS

About Senzime Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399,
info@fnca.se is Certified Adviser for Senzime. www.senzime.com

Taggar:

Om oss

Senzime utvecklar unika medicintekniska lösningar som gör det möjligt att följa patienters biokemiska och fysiologiska processer inför, under och efter operation. I portföljen ingår patientnära system som möjliggör automatiserad och kontinuerlig mätning av livskritiska ämnen som glukos och laktat i blod och vävnader samt system för att monitorera patienter som undergår narkos. Lösningarna syftar till att säkerställa maximal patientnytta, minska komplikationer i samband med operationer och minska vårdkostnader. Senzime verkar på växande marknader som idag enbart i Europa och USA värderas till över 10 miljarder SEK. Bolagets aktie är noterad på Nasdaq First North (ticker SEZI). FNCA är Certified Adviser för Senzime. www.senzime.com

Prenumerera

Media

Media

Dokument & länkar